MRNA:NASDAQ
Moderna Inc
$143.97
0.00%
(0.00) 1D
$143.60
arrow_downward
-0.26% (-0.37)todayPre-market
Closed: Sep 11, 4:00:01 PM GMT-4 · USD
search
All symbols
No data
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for MRNA...
Mkt. cap
57.48B
Avg. vol.
24.87M
Volume
165.21K
52-wk high
$176.66
52-wk low
$22.29
EPS
-$7.98
Beta
1.10
Shares outstanding
399.24M
No. of employees
5K
Mkt. cap
57.48B
Avg. vol.
24.87M
Volume
165.21K
52-wk high
$176.66
52-wk low
$22.29
EPS
-$7.98
Beta
1.10
Shares outstanding
399.24M
No. of employees
5K
News stories
From web sources and news partners
ad-hoc-news.de
·
2 hours ago
Moderna Inc. stock gains after FDA flu vaccine approval and Q2 2026 update
The Globe and Mail
·
8 hours ago
3 Cash-Burning Stocks We Approach with Caution
MarketBeat
·
1 day ago
Promising Biotech Stocks To Keep An Eye On - September 12th
Stocks Down Under
·
2 days ago
Moderna (NASDAQ:MRNA) Shares Surge as Cancer Vaccine Breakthrough Fuels Investor Interest
Profile
Moderna, Inc. is an American pharmaceutical and biotechnology company based in Cambridge, Massachusetts, that focuses on RNA therapeutics, primarily mRNA vaccines. These vaccines use a copy of a molecule called messenger RNA to carry instructions for proteins to produce an immune response. The company's name is derived from the terms "modified", "RNA", and "modern".
The company's commercial products are the Moderna COVID-19 vaccine sold under the brand names Spikevax and Mnexspike, a respiratory syncytial virus vaccine sold under the brand name Mresvia, and an influenza vaccine sold under the brand name Mflusiva. The company has 44 treatment and vaccine candidates, of which 37 have entered clinical trials. Candidates include possible vaccines for influenza, HIV, Epstein–Barr virus, the Nipah virus, chikungunya, human metapneumovirus, varicella zoster virus, as well as a cytomegalovirus vaccine, a Zika virus vaccine funded by the Biomedical Advanced Research and Development Authority, and three cancer vaccines.
In 2026, Time ranked Moderna as number one in their World's Most Impactful Companies list. Wikipedia
About Moderna Inc
Analyst ratings
Based on 20 analysts giving stock ratings to MRNA in the past 3 months
Hold
Buy
3
Hold
15
Sell
2
12-month forecast
Based on 20 Wall Street analysts offering 12 month price targets for MRNA in the last 3 months.
Highest
Current $143.97
$180.00 (+25.03%)
Average
$102.00 (-29.15%)
Lowest
$40.00 (-72.22%)
Analyst | Recommendation | Action | Price target | Projected | Date |
|---|---|---|---|---|---|
Nico Chen DBS | Hold | Maintained | $150.00 | +4.2% | 09/11/2026 |
Cory Kasimov Evercore ISI | Hold | Maintained | $80.00 | -44.4% | 09/11/2026 |
Harry Gillis Berenberg Bank | Hold | Maintained | $100.00 | -30.5% | 09/10/2026 |
Simon Baker CFA Rothschild & Co Redburn | Sell | Downgraded | $81.00 | -43.7% | 09/03/2026 |
Jasper Hellweg Argus Research | Buy | Upgraded | $180.00 | +25% | 08/27/2026 |
Alexandria Hammond Wolfe Research | Hold | Upgraded | - | - | 08/25/2026 |
Eliana Merle Barclays | Hold | Maintained | $125.00 | -13.2% | 08/24/2026 |
Michael Yee UBS | Hold | Maintained | $150.00 | +4.2% | 08/20/2026 |
Terence Flynn Morgan Stanley | Hold | Maintained | $89.00 | -38.2% | 08/19/2026 |
Andrew Tsai Jefferies | Hold | Reiterated | $60.00 | -58.3% | 08/19/2026 |
Alec Stranahan Bank of America Securities | Hold | Upgraded | $170.00 | +18.1% | 08/19/2026 |
Salveen Richter Goldman Sachs | Hold | Reiterated | $120.00 | -16.6% | 08/19/2026 |
Luca Issi RBC Capital | Hold | Maintained | $130.00 | -9.7% | 08/19/2026 |
Joseph Stringer Needham | Hold | Maintained | - | - | 08/19/2026 |
Jessica Fye J.P. Morgan | Sell | Maintained | $77.00 | -46.5% | 08/21/2026 |
Courtney Breen Bernstein | Hold | Reiterated | $45.00 | -68.7% | 08/20/2026 |
Geoff Meacham Citi | Hold | Maintained | $60.00 | -58.3% | 08/19/2026 |
Myles Minter William Blair | Buy | Upgraded | - | - | 08/19/2026 |
Edward Tenthoff Piper Sandler | Buy | Reiterated | $77.00 | -46.5% | 08/06/2026 |
Tyler Van Buren TD Cowen | Hold | Maintained | $40.00 | -72.2% | 07/31/2026 |
Unknown Analyst Berenberg Bank | Hold | Maintained | $45.00 | -68.7% | 07/31/2026 |
Unknown Analyst J.P. Morgan | Sell | Maintained | $40.00 | -72.2% | 05/20/2026 |
Mani Foroohar Leerink Partners | Sell | Maintained | $12.00 | -91.7% | 02/11/2026 |
Last report
Jul 31, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
-$1.97 / -$2.11
+6.64%beat
arrow_upward
Revenue / Est. (USD)
145.00M / 102.96M
+40.84%beat
arrow_upward
Fiscal Q2 2026 earnings call
youtube_liveWaiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
Revenue | 1.02B | 678.00M | 389.00M | 145.00M |
Cost of goods sold | 1.01B | 1.23B | 726.00M | 738.00M |
Cost of revenue | 1.01B | 1.23B | 726.00M | 738.00M |
Research and development expenses | - | - | - | - |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 268.00M | 308.00M | 173.00M | 216.00M |
Operating expense | 268.00M | 308.00M | 173.00M | 216.00M |
Total operating expenses | 1.28B | 1.54B | 899.00M | 954.00M |
Operating income | -260.00M | -857.00M | -510.00M | -809.00M |
Other non operating income | -4.00M | -2.00M | - | -2.00M |
EBT including unusual items | -187.00M | -799.00M | -1.33B | -767.00M |
EBT excluding unusual items | -191.00M | -797.00M | -455.00M | -761.00M |
Income tax expense | 13.00M | 27.00M | 9.00M | 15.00M |
Effective tax rate | -6.95% | -3.38% | -0.67% | -1.96% |
Other operating expenses | - | - | - | - |
Net income | -200.00M | -826.00M | -1.34B | -782.00M |
Net profit margin | -19.68% | -121.83% | -345.24% | -539.31% |
Earnings per share | -0.51 | -2.11 | -3.40 | -1.97 |
Interest and investment income | 73.00M | 70.00M | 72.00M | 67.00M |
Interest expense | - | -8.00M | -17.00M | -17.00M |
Net interest expenses | 73.00M | 62.00M | 55.00M | 50.00M |
Depreciation and amortization charges | - | - | - | - |
EBITDA | -208.00M | -790.00M | -451.00M | -746.00M |
Gain or loss from assets sale | - | - | - | - |
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider | Position | Type | Date | Shares | Amount |
|---|---|---|---|---|---|
Page 1